SCHEMBL2659710

SCHEMBL2659710

O=C(O)CCNC(=O)c1cccc(N(Cc2cccc(OC(F)(F)F)c2)C(=O)Oc2ccc3oc4ccccc4c3c2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.43
GCGR P47871 13/20 0.42
GIPR P48546 4/20 0.40
GLP1R P43220 2/20 0.40
BCHE P06276 1/20 0.39
HTR2C P28335 1/20 0.38
ACHE P22303 2/20 0.38
TRPM8 Q7Z2W7 1/20 0.37
ADCY6 O43306 1/20 0.37
ADCY3 O60266 1/20 0.37
ADCY9 O60503 1/20 0.37
ADCY5 O95622 1/20 0.37
ADCY8 P40145 1/20 0.37
ADCY7 P51828 1/20 0.37
ADCY2 Q08462 1/20 0.37
ADCY1 Q08828 1/20 0.37
ADCY4 Q8NFM4 1/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654369 0.94 GCGR (0.46) GCGRGIPRGLP1RHTR2CADCY6
SCHEMBL2655182 0.93 MAPK14 (0.48) MAPK14GCGRGIPRGLP1RADCY6
SCHEMBL2653269 0.88 GCGR (0.38) MAPK14GCGRGIPRGLP1RBCHE
SCHEMBL6758434 0.86 GCGR (0.55) GCGRGIPRGLP1RADCY6ADCY3
SCHEMBL2654344 0.86 GCGR (0.47) MAPK14GCGRGIPRGLP1RTRPM8
SCHEMBL2652571 0.86 GCGR (0.53) MAPK14GCGRGIPRGLP1RTRPM8
SCHEMBL2653622 0.82 GCGR (0.51) MAPK14GCGRGIPRGLP1R
SCHEMBL2653047 0.81 GCGR (0.50) GCGRGIPRGLP1RADCY6ADCY3
SCHEMBL2656385 0.81 GCGR (0.49) MAPK14GCGRGIPRGLP1R
SCHEMBL2653986 0.80 GCGR (0.44) MAPK14GCGRGIPRGLP1RADCY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152750-A1 Novel glucagon antagonists NOVO NORDISK A/S (DK) 2004-08-05 US disclosed
WO-2004056763-A2 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152750-A1 Novel glucagon antagonists GLP1R, GCGR, GIPR MAPK14 1428/4885GCGR 2/4885GIPR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.